Navigation Links
Higher co-payments increase chance of early discontinuation, inadequate use of breast cancer therapy
Date:12/11/2010

SAN ANTONIO A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone sensitive early-stage breast cancer.

Dawn L. Hershman, M.D., M.S., associate professor of medicine and epidemiology and co-director of the Breast Cancer Program at the Herbert Irving Comprehensive Cancer Center at Columbia University, presented detailed study results at the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010.

Previous research has identified several factors affecting patient compliance with use of adjuvant aromatase inhibitors, such as young and old age, severity of side effects and belief that the medication is useful.

Hershman and colleagues examined the impact of prescription co-payments on hormone therapy use. Working with the Medco Research Institute, a wholly owned subsidiary of Medco Health Solutions, Inc., anonymous patient information was used to target women older than 50 years who were prescribed aromatase inhibitors for early breast cancer.

"We looked at two different factors: women who discontinued use altogether or had no subsequent refills and those that did not refill their prescription on time or did not take the medication at least 80 percent of the time," said Hershman.

Results showed that of the 8,110 women aged 50 to 65 years, 21.1 percent stopped taking the medication and of those who properly continued with their regimen 10.3 percent did not take the medication as directed over the two-year period. Of the 14,050 women 65 years or older, almost 25 percent stopped taking the medication and of those who continued, 8.9 percent were non-adherent.

Co-payments were categorized as less than $30, between $30 and $89.99, and $90 or more. The 90-day co-payments ranged from $0 to $893.49.

In the 65 and older group, wome
'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Snakes, salamanders and other creatures thrive in areas with higher deer populations
2. Children distressed by family fighting have higher stress hormones
3. Researchers push nature beyond its limits to create higher-density biofuels
4. Teenage boys who eat fish at least once a week achieve higher intelligence scores
5. Genetic irregularities linked to higher risk of COPD among smokers
6. Business, scientific, higher education groups laud President Obamas commitment to science
7. Immigrant women may be at higher risk of having a baby with a birth defect
8. People of higher socioeconomic status choose better diets -- but pay more per calorie
9. Bioethanols impact on water supply 3 times higher than once thought
10. Metabolic syndrome risk factors drive significantly higher health care costs
11. Ethiopias climate 27 million years ago had higher rainfall, warmer soil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
(Date:4/6/2015)... 6, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND ... NXT-ID introduces a new revolutionary method and ... the use of miniature antenna modules for multiple ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... team of neuroengineers based at Brown University has developed ... of relaying real-time broadband signals from up to 100 ... novel low-power device, described in the Journal of ... models for more than year, a first in the ...
... long-term consequences of childhood obesity are well documented, some ... more time to the 3 Rs in educationreading, writing, ... leaving out an important fourth Raerobicscould actually be counterproductive ... for publication in The Journal of Pediatrics ...
... at Wake Forest Baptist Medical Center and colleagues have ... bone marrow that have the natural ability to migrate ... potential to restore healthy tissue in patients with inflammatory ... have IBD, which is characterized by frequent diarrhea and ...
Cached Biology News:Brown unveils novel wireless brain sensor 2Brown unveils novel wireless brain sensor 3Brown unveils novel wireless brain sensor 4Reading, writing, arithmetic, and aerobics -- Evaluating the new 'R' in academic performance 2Research supports promise of cell therapy for bowel disease 2
(Date:4/24/2015)... N.J. , April 24, 2015  Navitas Life Sciences ... as Head of Clinical and Regulatory Services. Shalabh is ... been a co-founder and CEO of Kinapse, as well as ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... Jim Tizzard commented "I am delighted to welcome Shalabh ...
(Date:4/23/2015)... 23, 2015 The Thomas Brain ... conduct a groundbreaking pilot study to see if ... in as little as three to six months. ... and nutritional medicine—will aggressively target and simultaneously treat ... our aging brain. These include oxidative stress, neuroinflammation, ...
(Date:4/23/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology and medical device industries, ... the United States , today announced ... quarter of 2015 after the New York Stock Exchange ... Thursday morning, May 14, 2015 Shanghai time). The earnings ...
(Date:4/23/2015)... April 23, 2015 Glemser ... the first EMC® Enterprise Content Division (ECD) Certified ... EMC Documentum® for Life Sciences Solution Suite ... knowledge and capabilities to provide life sciences companies ... , The EMC Documentum Solution Suite offers ...
Breaking Biology Technology:Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... of HER1, HER2 and HER3 Assays to Provide Unique ... Facilitate Development of Personalized Cancer Therapies, SOUTH SAN ... ) today announced that the company,s HER1,and HER3 Quantitative ... on Monogram,s VeraTag(TM) platform, the HER1 and,HER3 assays provide ...
... Meeting of Shareholders to be Reconvened on May 29, ... Therapeutics,Corporation (Nasdaq: UTHR ) (the Company) held its ... 2008. The Company,s,shareholders voted to approve the election of ... directors with terms expiring in 2011. The,Company,s shareholders also ...
... IRVINE, Calif., May 1 Edwards Lifesciences,Corporation (NYSE: ... and technologies to,treat advanced cardiovascular disease, will host ... 2008 beginning at 10:00 a.m. PT (1:00 pm,ET) ... A live webcast of the meeting will be ...
Cached Biology Technology:HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 2HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 3HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 4HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 5United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders 2United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders 3Edwards Lifesciences to Webcast Annual Stockholders Meeting 2
G-protein coupled purinergic receptor P2Y8...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: